HighTower Advisors
CLDX icon

HighTower Advisors’s Celldex Therapeutics CLDX Stock Holding History

HighTower Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,218
Closed -$350K – 3279
2022
Q1 		$350K Buy
+10,218
New +$327K ﹤0.01% 2412
2021
Q4 		– Sell
-4,147
Closed -$225K – 3322
2021
Q3 		$225K Buy
+4,147
New +$195K ﹤0.01% 2627
2019
Q4 		– Sell
-11,275
Closed -$21K – 2405
2019
Q3 		$21K Sell
11,275
-637
-5% -$1.47K ﹤0.01% 2272
2019
Q2 		$31K Buy
+11,912
New +$40.5K ﹤0.01% 2239
2019
Q1 		– Sell
-1,903
Closed -$2K – 2312
2018
Q4 		$2K Sell
1,903
-1,458
-43% -$7.16K ﹤0.01% 2168
2018
Q3 		$19K Hold
3,361
– – ﹤0.01% 2169
2018
Q2 		$22K Sell
3,361
-473
-12% -$6.32K ﹤0.01% 2105
2018
Q1 		$135K Sell
3,834
-10,000
-72% -$387K ﹤0.01% 1938
2017
Q4 		$588K Sell
13,834
-1,547
-10% -$66.3K ﹤0.01% 1366
2017
Q3 		$659K Sell
15,381
-4
-0% -$150 0.01% 1308
2017
Q2 		$568K Sell
15,385
-467
-3% -$20.7K 0.01% 1303
2017
Q1 		$858K Sell
15,852
-479
-3% -$24.9K 0.01% 1102
2016
Q4 		$869K Buy
16,331
+458
+3% +$26.1K 0.01% 1029
2016
Q3 		$959K Sell
15,873
-317
-2% -$19.7K 0.01% 936
2016
Q2 		$1.06M Sell
16,190
-315
-2% -$20K 0.01% 856
2016
Q1 		$940K Buy
16,505
+13,540
+457% +$1.52M ﹤0.01% 1068
2015
Q4 		$704K Sell
2,965
-53
-2% -$11.6K 0.01% 1145
2015
Q3 		$480K Buy
+3,018
New +$854K 0.01% 1221

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

HighTower Advisors's CLDX Position: Q2 2022 in Review

HighTower Advisors sold out of Celldex Therapeutics (CLDX) in Q2 2022, closing a stake of 10,218 shares — an estimated $350K sold.

HighTower Advisors first reported a position in CLDX in Q3 2015 and held it in 18 quarters. The position peaked at $1.06M in Q2 2016. 157 funds tracked by Wall St. Rank hold CLDX as of Q2 2022.

  • HighTower Advisors reported no remaining Celldex Therapeutics position as of Q2 2022 after selling out during the quarter.
  • HighTower Advisors sold 10,218 Celldex Therapeutics shares in Q2 2022, an estimated $350K.
  • HighTower Advisors first reported a position in Celldex Therapeutics in Q3 2015 and held it in 18 quarters.
  • HighTower Advisors's Celldex Therapeutics position peaked at $1.06M in Q2 2016.
  • 157 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2022.

Based on HighTower Advisors's 13F filing for Q2 2022, filed 10 Aug 2022.